Genomic landscape of DNA repair genes in cancer

DNA repair genes are frequently mutated in cancer, yet limited data exist regarding the overall genomic landscape and functional implications of these alterations in their entirety. We created comprehensive lists of DNA repair genes and indirect caretakers. Mutation, copy number variation (CNV), and expression frequencies of these genes were analyzed in COSMIC. Mutation co-occurrence, clinical outcomes, and mutation burden were analyzed in TCGA. We report the 20 genes most frequently with mutations (n > 19,689 tumor samples for each gene), CNVs (n > 1,556), or up- or down-regulated (n = 7,998). Mutual exclusivity was observed as no genes displayed both high CNV gain and loss or high up- and down-regulation, and CNV gain and loss positively correlated with up- and down-regulation, respectively. Co-occurrence of mutations differed between cancers, and mutations in many DNA repair genes were associated with higher total mutation burden. Mutation and CNV frequencies offer insights into which genes may play tumor suppressive or oncogenic roles, such as NEIL2 and RRM2B, respectively. Mutual exclusivities within CNV and expression frequencies, and correlations between CNV and expression, support the functionality of these genomic alterations. This study provides comprehensive lists of candidate genes as potential biomarkers for genomic instability, novel therapeutic targets, or predictors of immunotherapy efficacy.

[1]  A. Ronen,et al.  Human DNA repair genes , 2001, Environmental and molecular mutagenesis.

[2]  Nicola J. Curtin,et al.  DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.

[3]  Richard D. Wood,et al.  Human DNA Repair Genes , 2001, Science.

[4]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[5]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[7]  F. Dietlein,et al.  Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. , 2014, Trends in genetics : TIG.

[8]  T. Lindahl,et al.  Quality control by DNA repair. , 1999, Science.

[9]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[10]  K. Kinzler,et al.  APC mutations in colorectal tumors with mismatch repair deficiency. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[12]  Peter Bouwman,et al.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance , 2012, Nature Reviews Cancer.

[13]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[14]  A. Fischer,et al.  Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Yusuke Nakamura,et al.  Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival , 2014, Clinical Cancer Research.

[16]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.

[17]  J. Neal,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[19]  A. Kauffmann,et al.  Overexpression of DNA repair genes is associated with metastasis: a new hypothesis. , 2008, Mutation research.

[20]  P. Hanawalt,et al.  A phylogenomic study of DNA repair genes, proteins, and processes. , 1999, Mutation research.

[21]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[22]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[23]  C. Bucana,et al.  Direct correlation between DNA repair capacity and metastatic potential of K-1735 murine melanoma cells. , 1997, The Journal of investigative dermatology.

[24]  L. Loeb,et al.  A mutator phenotype in cancer. , 2001, Cancer research.

[25]  E. Kohn,et al.  Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors , 2014, Front. Oncol..

[26]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[27]  L. Aaltonen,et al.  Somatic microsatellite mutations as molecular tumor clocks , 1996, Nature Medicine.

[28]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[29]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[30]  W. Lambert,et al.  The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. , 1994, Archives of dermatology.

[31]  Scott D. Brown,et al.  Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival , 2014, Genome research.

[32]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[33]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[34]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[35]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[36]  Mary B. Daly,et al.  BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer , 2013 .

[37]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[38]  T. Aparicio,et al.  PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .

[39]  J. Bartek,et al.  The DNA-damage response in human biology and disease , 2009, Nature.

[40]  D. Tripathy,et al.  Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. , 2004, The oncologist.

[41]  F. Marincola,et al.  Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors , 2013, Journal of Immunotherapy for Cancer.

[42]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[43]  R. Wood,et al.  DNA polymerases and cancer , 2011, Nature Reviews Cancer.

[44]  Kieran Sheahan,et al.  Lynch Syndrome: An Updated Review , 2014, Genes.

[45]  J. Wolchok,et al.  Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.

[46]  C. Mathew,et al.  Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.

[47]  Jun Liu,et al.  Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening , 2014, BMC Cancer.

[48]  E. Latulippe,et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.

[49]  Zoltan Szallasi,et al.  Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations , 2013, PloS one.

[50]  E. Koonin,et al.  Conserved domains in DNA repair proteins and evolution of repair systems. , 1999, Nucleic acids research.